What are the indications, recommended dosing regimens, therapeutic drug monitoring targets, safety monitoring parameters, contraindications, and alternative therapies for cyclosporine?

Cyclosporine in Dermatology: Clinical Guide

Indications

Cyclosporine is FDA-approved for severe psoriasis and atopic dermatitis in patients ≥16 years, but is widely used off-label for numerous inflammatory dermatoses. 1, 2

Licensed indications:

• Severe psoriasis vulgaris (including erythrodermic, generalized pustular, palmoplantar pustulosis, acrodermatitis continua of Hallopeau, psoriatic nail dystrophy, and psoriatic arthropathy)
• Severe atopic dermatitis

Common off-label dermatologic uses: 1

• Chronic spontaneous urticaria
• Lichen planus
• Pyoderma gangrenosum
• Behçet disease
• Immunobullous diseases
• Connective tissue diseases
• Photodermatoses
• Alopecia areata
• Granuloma annulare

Dosing Regimens

Psoriasis

Start at 2.5 mg/kg/day divided twice daily (BID) for at least 4 weeks. 2 If rapid control is needed in very severe disease, start at 5 mg/kg/day. 1

Dose escalation algorithm:

• If inadequate response after 4 weeks: increase by 0.5 mg/kg/day every 2 weeks
• Maximum dose: 4 mg/kg/day
• Discontinue if no response after 6 weeks at maximum tolerated dose 2

Once controlled: Taper by 0.5-1 mg/kg increments to lowest effective maintenance dose. 1 Doses below 2.5 mg/kg/day may maintain remission in 60% of patients. 2

Duration: Short courses of 2-6 months are strongly preferred over continuous therapy to minimize nephrotoxicity risk. 1 Treatment beyond 1 year is not recommended. 2

Atopic Dermatitis

Use the same dosing strategy as psoriasis: 2.5-5 mg/kg/day divided BID. 1 Body-weight-independent dosing (150-300 mg/day) has shown efficacy, with 150 mg/day offering better renal tolerability. 3

Rheumatoid Arthritis

Start at 2.5 mg/kg/day divided BID. 2

Dose escalation:

• If inadequate response after 8 weeks with good tolerability: increase by 0.5-0.75 mg/kg/day
• Repeat at 12 weeks if needed
• Maximum: 4 mg/kg/day
• Discontinue if no benefit by 16 weeks 2

When combined with methotrexate (up to 15 mg/week), most patients respond to ≤3 mg/kg/day cyclosporine. 2

Administration

• Take on empty stomach or before meals 1
• Once daily or divided BID dosing are equally effective 1
• Avoid grapefruit and grapefruit juice (increases cyclosporine levels) 1, 2
• Modified formulations (Neoral) are NOT interchangeable with original Sandimmune without dose adjustment 2

Therapeutic Drug Monitoring

Routine cyclosporine blood level monitoring is NOT required for dermatologic indications (unlike transplant patients). 1 However, monitoring may be useful in:

• Suspected poor absorption
• Drug interaction concerns
• Toxicity assessment

For transplant patients: Trough levels (C0) are standard, though C0.5h and C6h show highest correlation with AUC. 4 Target ranges vary by organ and protocol.

Safety Monitoring Parameters

Baseline Requirements 1

Laboratory:

• Two separate serum creatinine measurements (calculate mean baseline)
• Complete blood count
• Liver function tests
• Urea and electrolytes
• Hepatitis B and C serology
• Varicella zoster serology (if no history of chickenpox)

Clinical:

• Blood pressure measurement
• Skin examination for malignancies

Ongoing Monitoring 1

First 2 months:

• Serum creatinine: every 2 weeks
• Blood pressure: every 2 weeks

After 2 months (if stable):

• Serum creatinine: every 2-3 months
• Blood pressure: every 2-3 months
• Clinical follow-up: maximum 3-month intervals

Critical monitoring principle: Compare creatinine changes to patient's individual baseline, NOT population normal ranges (muscle mass affects baseline values). 1

Dose Adjustment for Toxicity

Serum creatinine elevation >30% above baseline: 1

• Repeat within 2 weeks
• If sustained: reduce dose by 25-50%
• If reduction ineffective or elevation severe: discontinue

Hypertension or other significant adverse events: 2

• Reduce dose by 25-50%
• If uncontrolled: discontinue

For psoriasis: Reduce dose if creatinine rises ≥25% above baseline 2

Contraindications

Absolute Contraindications 1

• Uncontrolled hypertension
• Abnormal baseline renal function
• Active serious infections
• Malignancy (current or recent)

Relative Contraindications/Cautions

• Severe hepatic dysfunction (impairs metabolism)
• Pregnancy (use only if benefit outweighs risk)
• Breastfeeding (excreted in milk) 1
• Inability to comply with monitoring 1

Specific to Rheumatoid Arthritis and Psoriasis 2

Patients with impaired renal function should NOT receive cyclosporine for these indications.

Drug Interactions

Cyclosporine is metabolized by CYP3A4 and P-glycoprotein. 1

Drugs that INCREASE cyclosporine levels (reduce dose):

• Azole antifungals (ketoconazole, fluconazole)
• Macrolide antibiotics (erythromycin, clarithromycin)
• Calcium channel blockers (diltiazem, verapamil)
• Protease inhibitors
• Grapefruit juice

Drugs that DECREASE cyclosporine levels (may need dose increase): 1

• Rifampin
• Phenytoin, phenobarbital, carbamazepine
• St. John's wort
• Nafcillin
• Terbinafine

Nephrotoxic drug combinations to avoid:

• NSAIDs (use with extreme caution)
• Aminoglycosides
• Amphotericin B
• Other nephrotoxic agents

Alternative Therapies

For Psoriasis

Biologics are more effective than cyclosporine for long-term management. A meta-analysis of 16,696 patients showed infliximab, adalimumab, and ustekinumab superior to conventional therapies including cyclosporine. 1

Other systemic options:

• Methotrexate (comparable efficacy, different toxicity profile)
• Acitretin (less effective: 47% vs 71% PASI reduction with cyclosporine) 1
• Apremilast
• Biologics (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors)

Combination therapy: Cyclosporine + methotrexate shows enhanced efficacy in psoriatic arthritis. 1

For Atopic Dermatitis

• Dupilumab (preferred for long-term management)
• Methotrexate
• Azathioprine
• Mycophenolate mofetil
• JAK inhibitors (upadacitinib, abrocitinib)

Critical Clinical Pearls

Intermittent short courses are safer than continuous therapy - use for acute flares, then rotate to other treatments. 1

Combine with topical therapy to reduce cyclosporine dose requirements and maintain remission during tapering. 1

Avoid live vaccines during treatment; other vaccines may be less effective. 1

Rebound is uncommon after stopping cyclosporine (unlike some other treatments). Relapse typically occurs 6-16 weeks after discontinuation. 2

Narrow therapeutic index - formulation changes require careful monitoring and potential dose adjustment. 1

Nephrotoxicity is dose-dependent and usually reversible when guidelines are followed ("go low, go slow" approach). 5